BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:19:21 PM | Browse: 20 | Download: 44
 |
Received |
|
2024-11-28 07:55 |
|
Peer-Review Started |
|
2024-11-28 07:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-18 10:29 |
|
Revised |
|
2025-01-10 14:39 |
|
Second Decision |
|
2025-02-21 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-21 07:36 |
|
Articles in Press |
|
2025-02-21 07:36 |
|
Publication Fee Transferred |
|
2025-01-14 02:40 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-07 08:22 |
|
Publish the Manuscript Online |
|
2025-03-25 16:19 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Fei Lu, Hong-Wei Zhang, Xiao Chang and Yong-Ze Guo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yong-Ze Guo, MD, Professor, Department of Gastroenterology, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan 056002, Hebei Province, China. guoyongze69@126.com |
| Key Words |
Colorectal cancer; F-box protein 22; Biomarker; Prognosis; Tumor immunology |
| Core Tip |
The precise role of the F-box protein 22 (FBXO22) gene in post-operative colon cancer patients remains to be fully elucidated. Utilizing bioinformatics assessments alongside cellular experimentation, researchers observed that the expression of the FBXO22 gene is markedly higher in colon cancer tissues when compared to normal colonic tissues. Patients suffering from colon cancer who present with increased FBXO22 gene levels tend to have decreased survival rates and show resistance to various chemotherapy agents. The elevated levels of the FBXO22 gene are associated with a reduction in the infiltration of immune cells that target tumors. Laboratory experiments demonstrate that reducing the activity of the FBXO22 gene hinders the growth and movement of colon cancer cells. The evidence suggests that the FBXO22 gene may facilitate the advancement of colon cancer, be associated with the onset of resistance to chemotherapy among post-operative colon cancer patients, and could act as an indicator of poor outcomes for these individuals. Consequently, targeting FBXO22 could represent a novel approach for treating colon cancer. |
| Publish Date |
2025-03-25 16:19 |
| Citation |
<p>Lu XF, Zhang HW, Chang X, Guo YZ. F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance. <i>World J Gastrointest Oncol</i> 2025; 17(4): 102913</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/102913.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.102913 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
